Aggregator

Jay W. Lorsch, the Louis E. Kirstein Professor of Human Relations, Emeritus at Harvard Business School (HBS) and a renowned expert on corporate boards who also did seminal early work on the relationship between environment and the organization, passed away on August 5 at the age of 92. In a distinguished career that spanned over five decades, Lorsch influenced generations of students and practitioners through his teaching and scholarship that contributed significantly to the shape of modern corporate governance and the development of new approaches to understanding organizational behavior.

H. Kent Bowen, a pioneering scholar in technology and operations management, and a beloved mentor, passed away on July 17, 2025, at the age of 83. Known for his visionary leadership and deep commitment to education and industry collaboration, Kent Bowen leaves behind a legacy that helped to shape the field of manufacturing and operations strategy across academia and practice.

While it's still too early to know how many knowledge jobs AI might replace, Christopher Stanton says the "fast-diffusing" technology is reshaping business.

“There are essentially three parties who can end up bearing the cost of tariffs,” says economist Alberto Cavallo, head of the Pricing Lab at Harvard Business School. “It could be foreign exporters, it could be the US firms that are bringing those goods into the US, or it could be US consumers.”

The group of former Intel board members— Charlene Barshefsky, Reed Hundt, James Plummer, and David Yoffie—pointed out that the company is on its fourth CEO in seven years with little improvement in results. They argued that only a dramatic break could restore Intel’s competitiveness and protect U.S. national security interests, with a rescue plan focused specifically on emancipating Intel’s “Foundry” business, the manufacturing assets from which Intel produces semiconductor chips for its own products and for third-party customers.

A little over five years ago, the Trump administration announced Operation Warp Speed to deliver a vaccine for COVID-19. It was one of the most stunning successes of Trump’s first term. Recognizing a crisis, the U.S. government facilitated a public-private partnership that likely saved millions of lives in record time. Now we must do it again. As a country, we have a strategic imperative to win in artificial intelligence and secure our supply chains for critical technologies, including communications, computing, and advanced military systems. Time is of the essence. Yet the Administration’s plans for AI and self-sufficiency are in serious jeopardy unless we have American-owned, leading-edge chip manufacturing plants on American soil.

Alberto Cavallo, a professor at Harvard Business School who is tracking prices at four major retailers, found that prices of imported goods are up around 3% since tariffs started rising. Prices of household goods, furniture and electronics have risen especially quickly.

And while inflation was fairly modest, prices were still going up, just at a gentle rate that most consumers would be hard-pressed to detect. Since early March, prices for imported goods have risen about 3 percent on average — with larger increases on goods from China, according to Alberto Cavallo, a Harvard economist.

Andrew Biggs’s “A Risky Plan for Social Security” warns that the bipartisan reform plan to provide long-term solvency for the Social Security system proposed by Sens. Bill Cassidy (R., La.) and Tim Kaine (D., Va.) is too risky (op-ed, July 25). But the Cassidy-Kaine plan is much less risky than ignoring Social Security’s current $25 trillion funding gap and allowing its trust fund to be depleted by 2033.

Work described in this story was made possible in part by federal funding supported by taxpayers. At Harvard Medical School, the future of efforts like this — done in service to humanity — now hangs in the balance due to the government’s decision to terminate large numbers of federally funded grants and contracts across Harvard University. In a discovery that could expand the array of current cancer immunotherapy treatments, scientists at Harvard Medical School have identified a new molecular brake that hinders the ability of T cells to attack tumors. The research, published Aug. 12 in Nature…